The aromatase inhibitor letrozole (Femara) significantly reduces the risk of relapse compared with tamoxifen (Nolvadex) for postmenopausal women with hormone-responsive breast cancer, according to the results of the first clinical trial to incorporate both a head-to-head comparison of the two drugs and a sequencing of both agents during the first five years following breast cancer surgery.
Go to Previous Page
Go to Next Page